Neurizon Secures $44M to Fund NUZ-001 Phase 2/3 ALS Trial Starting Q1 2026

Neurizon Therapeutics Limited (ASX: NUZ) has secured approximately $44.2M in funding to support its participation in the HEALEY ALS Platform Trial for lead asset NUZ-001. The comprehensive package comprises a $7.1M Placement at $0.08 per share, a 2-for-5 Entitlement Offer targeting up to $17.1M, and a strategic $20M convertible note facility with New York-based Obsidian Global GP, LLC. Directors and management have committed $0.8M (subject to shareholder approval), demonstrating strong alignment with the company’s clinical strategy ahead of first patient dosing in Q1 CY2026.

Breaking Down the Three-Part Capital Structure

The funding structure balances immediate capital requirements with flexibility to pursue value-maximising partnerships. The three-component approach minimises upfront dilution whilst providing execution certainty for the pivotal Phase 2/3 trial.

Placement and Director Participation

Neurizon has secured firm commitments to raise $7.1M (before costs) through the issue of approximately 89.1M new shares at $0.08 per share. The offer price represents a 27.3% discount to the last traded price of $0.11 and a 27.3% discount to the 5-day volume-weighted average price.

Director and management participation totalling $0.8M requires shareholder approval at an upcoming extraordinary general meeting. This investment demonstrates board confidence in the clinical development pathway and aligns leadership interests with shareholder outcomes.

Entitlement Offer Structure

Eligible shareholders will be offered the opportunity to acquire 2 new shares for every 5 shares held as at 7:00pm on 30 December 2025 (Record Date) at $0.08 per share. The non-renounceable structure means entitlements cannot be traded, and shareholders who do not participate will experience dilution.

The Entitlement Offer includes an Oversubscription Facility, allowing eligible shareholders who take up their full entitlement to apply for additional shares. Allocation of oversubscription shares remains at the company’s discretion and may be subject to scale-back. Any remaining shortfall following oversubscriptions may be placed within 3 months of the offer closing at the board’s discretion.

What Does the HEALEY ALS Platform Trial Mean for Neurizon Shareholders?

The HEALEY ALS Platform Trial represents an adaptive pivotal registration Phase 2/3 clinical trial created in partnership with the Network of Excellence for ALS (NEALS). This trial design offers material advantages over traditional standalone trials through shared infrastructure, accelerated timelines, and improved cost efficiencies.

The trial evaluates multiple investigational drugs simultaneously across shared clinical sites, reducing start-up delays and improving patient enrolment efficiency. For Neurizon, participation validates NUZ-001 as a Phase 3-ready asset alongside programmes backed by leading academic institutions, regulators, and industry partners.

The trial comprises two distinct phases:

1. Randomised Clinical Trial (RCT) Phase (36 weeks): A multicentre, double-blind, placebo-controlled evaluation assessing NUZ-001’s safety and efficacy against standard care.

2. Active Treatment Extension (ATE) Phase (36 weeks): An open-label extension phase monitoring longer-term treatment effects and durability of response.

This structure enables Neurizon to evaluate the promising safety and early efficacy signals observed in earlier studies within a larger, registration-quality clinical setting. The adaptive design allows for interim analyses that could accelerate regulatory approval timelines compared to conventional trial architectures.

Participation enhances Neurizon’s partnering appeal by providing globally recognised validation of NUZ-001’s clinical potential. The trial’s regulatory acceptance across major jurisdictions positions the company to pursue accelerated approval pathways in multiple markets simultaneously.

How Will Neurizon Fund Its NUZ-001 Clinical Trial?

The company’s comprehensive funding strategy extends beyond the capital raise to include existing cash reserves and future AusIndustry R&D tax rebates. This diversified approach provides coverage for both the RCT and ATE phases of the HEALEY ALS Platform Trial whilst preserving optionality for alternative funding sources.

Any capital raised beyond trial requirements will support broader platform development initiatives. Management has confirmed ongoing pre-clinical work exploring NUZ-001’s potential across additional neurodegenerative diseases, including Huntington’s Disease and Frontotemporal Dementia (FTD).

The milestone-aligned drawdown structure of the Obsidian facility allows Neurizon to access capital progressively, matching funding needs to clinical and regulatory achievements. This approach minimises unnecessary dilution whilst maintaining financial flexibility to pursue grant funding, regional licensing arrangements, or partnering deals as the clinical programme advances.

CEO Dr Michael Thurn emphasised the strategic value of this structure: “This funding package fundamentally transforms Neurizon’s position and reflects the market’s recognition of NUZ-001 as a Phase 3-ready asset of international significance. The structure of this funding, which combines new sophisticated and professional investors and existing shareholder support, director alignment and a strategically flexible facility from Obsidian provides Neurizon with the balance sheet strength to pursue value-maximising outcomes rather than any future reactive financing requirements.”

What is the Obsidian Convertible Note Facility for Neurizon?

Obsidian Global GP, LLC is a New York-based alternative investment firm with an established track record funding growth-stage biotechnology companies listed on Nasdaq and ASX. The firm’s structured investments align with portfolio companies’ capital requirements and long-term development timelines, offering operational flexibility with reduced upfront dilution.

Obsidian’s investment follows extensive due diligence of Neurizon’s clinical asset and regulatory pathway. The financing terms have been structured to support HEALEY ALS Platform Trial execution whilst maintaining balance sheet discipline.

Facility Terms and Structure

The $20M aggregate facility operates over 24 months from the date of first purchase. The initial drawdown will be $5M, with subsequent tranches ranging between $2.5M and $5M at Neurizon’s discretion (or as mutually agreed).

Drawdown timing includes specific restrictions: the first subsequent purchase cannot occur before 1 September 2026, and subsequent purchases must be spaced at least 6 months apart. For the first subsequent purchase, Neurizon must maintain a cash balance of at least $9.5M immediately prior to drawdown.

The facility is secured by a general security agreement over the company’s assets. Neurizon has also entered into a deed of priority with its R&D rebate financier to regulate priority between security interests.

Conversion Mechanics

The facility incorporates a dual conversion price structure providing flexibility based on market conditions:

Fixed Conversion Price: For notes issued at the initial purchase, the fixed conversion price is A$0.165. For subsequent purchases, the fixed price equals 150% of the 5-day VWAP for the 5 trading days immediately prior to purchase.

Variable Conversion Price: Subject to timing limitations, the investor may convert at 94% of the average of the 5 lowest daily VWAPs during the 20 trading days prior to conversion notice.

Variable conversions cannot occur within 60 days of purchase (unless an event of default occurs). The investor is restricted from converting where such conversion would result in holding more than 9.99% of total shares on issue.

The facility requires Neurizon to initially place 10M shares with Obsidian (subject to shareholder approval), with a potential further 15M shares available during the facility term under specific conditions. These placement shares serve an offsetting function, available to satisfy share issuance obligations upon note conversion at the investor’s discretion.

Why the Structured Approach Matters

Traditional equity raises typically result in immediate dilution for existing shareholders at a fixed price point. Neurizon’s three-part structure distributes dilution across multiple instruments whilst preserving strategic optionality.

The convertible facility’s milestone-aligned drawdown mechanism ties capital deployment to clinical progress. This structure ensures funding availability contingent on achieving development milestones, rather than requiring full upfront commitment regardless of trial outcomes.

The board’s selection of this funding architecture demonstrates fiduciary discipline in capital allocation. By maintaining the ability to pursue grant funding (such as AusIndustry R&D rebates), regional licensing arrangements, or global partnering opportunities, Neurizon preserves negotiating leverage as clinical data emerges.

This diversified approach positions Neurizon to negotiate partnerships from a position of financial strength rather than capital necessity. As trial data becomes available, the company retains flexibility to optimise its capital structure based on partnering interest, regulatory feedback, or additional grant funding opportunities.

Regulatory Pathway and Global Partnering Implications

The HEALEY ALS Platform Trial’s adaptive design holds regulatory acceptance across major jurisdictions, potentially accelerating approval timelines compared to traditional sequential trial approaches. Adaptive trial structures enable interim analyses that can support earlier regulatory engagement and expedited review pathways.

Neurizon’s strengthened balance sheet positions the company to pursue proactive partnering discussions rather than engaging from a position of capital constraint. The funding certainty through Q1 CY2026 and beyond enables management to focus on value-maximising partnership structures rather than reactive financing requirements.

Management has indicated intentions to pursue accelerated global regulatory pathways alongside regional and worldwide partnering initiatives. The combination of a globally recognised trial platform, validated clinical approach, and financial stability creates optimal conditions for partnership negotiations on favourable commercial terms.

Timeline to First Patient Dosing

The company has confirmed first patient dosing in the HEALEY ALS Platform Trial will occur in Q1 CY2026, representing a near-term operational catalyst for monitoring clinical execution.

The funding package’s staged implementation aligns with this timeline:

• 30 December 2025: Entitlement Offer Record Date establishes eligible shareholders

• 21 January 2026: Entitlement Offer closes, with results announced 27 January 2026

• February 2026: General Meeting to approve director/management placement participation and convertible note facility

• Q1 CY2026: First patient dosed in HEALEY ALS Platform Trial (RCT phase commences)

This sequence ensures all funding components are in place prior to trial commencement, providing execution certainty as Neurizon transitions from preparatory activities to active clinical operations. Shareholders can track progress against these milestones as the company advances NUZ-001 through this pivotal development stage.

Ready To Discover Neurizon’s Pioneering ALS Trial Progress?

Neurizon Therapeutics is advancing its NUZ-001 asset through a strategically funded Phase 2/3 HEALEY ALS Platform Trial, underpinned by $44.2M in committed capital supporting clinical milestones ahead of first patient dosing in Q1 CY2026. This unique adaptive study offers accelerated timelines and global regulatory engagement potential, positioning Neurizon at the forefront of neurodegenerative disease treatment innovation.

For a deeper understanding of Neurizon’s clinical programmes, funding structure, and partnership strategy, visit the Neurizon investor centre to explore the full scope of this transformative biotech opportunity.